Neutralization of Different Variants of SARS-CoV-2 by a F(ab')2 Preparation from Sera of Horses Immunized with the Viral Receptor Binding Domain.
Mariajose Rodriguez-NuñezMariana Del Valle CepedaCarlos BelloMiguel Angel LopezYoneira SulbaranCarmen Luisa LoureiroFerdinando LiprandiRossana Celeste JaspeFlor Helene PujolHéctor Rafael RangelPublished in: Antibodies (Basel, Switzerland) (2023)
The Receptor Binding Domain (RBD) of SARS-CoV-2, the virus responsible for the COVID-19 pandemic, is the functional region of the viral Spike protein (S), which is involved in cell attachment to target cells. The virus has accumulated progressively mutations in its genome, particularly in the RBD region, many of them associated with immune evasion of the host neutralizing antibodies. Some of the viral lineages derived from this evolution have been classified as Variant of Interest (VOI) or Concern (VOC). The neutralizing capacity of a F(ab')2 preparation from sera of horses immunized with viral RBD was evaluated by lytic plaque reduction assay against different SARS-CoV-2 variants. A F(ab')2 preparation of a hyperimmune serum after nine immunizations with RBD exhibited a high titer of neutralizing antibodies against the ancestral-like strain (1/18,528). A reduction in the titer of the F(ab')2 preparation was observed against the different variants tested compared to the neutralizing activity against the ancestral-like strain. The highest reduction in the neutralization titer was observed for the Omicron VOC (4.7-fold), followed by the Mu VOI (2.6), Delta VOC (1.8-fold), and Gamma VOC (1.5). Even if a progressive reduction in the neutralizing antibodies titer against the different variants evaluated was observed, the serum still exhibited a neutralizing titer against the Mu VOI and the Omicron VOC (1/7113 and 1/3918, respectively), the evaluated strains most resistant to neutralization. Therefore, the preparation retained neutralizing activity against all the strains tested.
Keyphrases
- sars cov
- dengue virus
- respiratory syndrome coronavirus
- copy number
- molecularly imprinted
- zika virus
- escherichia coli
- binding protein
- multiple sclerosis
- single cell
- gene expression
- coronary artery disease
- dna binding
- mesenchymal stem cells
- signaling pathway
- cell therapy
- small molecule
- coronavirus disease
- protein protein
- cell cycle arrest
- genome wide